Ronda Stryker's $137M SYK Trim — But She Just Reaffirmed 4%

Stryker Corporation director Ronda E. Stryker disposed of roughly 375,240 SYK shares across February 4 and February 5, 2026, generating approximately $137 million in proceeds at a weighted price near $365 per share. Two months later, on April 14, she filed a Schedule 13D/A reaffirming a 4.0% beneficial ownership stake in the medical-devices maker — 15,223,331 shares worth roughly $5.6 billion at the May 9 close of $367. The two-step sequence — open-market trim, then a renewed control-block disclosure — is the signal worth reading.

The Stryker family complex around Stryker Corp is one of the more opaque institutional holder structures on the medtech tape. Between Ronda Stryker's direct stake, the Greenleaf Trust block, and the multiple Vanguard family entities that emerged from this spring's reporting reshuffle, the post-February ownership picture matters more for investors trying to size float and conviction than the dollar-headline sale itself.

What the February Form 4 actually shows

The filing, accession 0001242914-26-000002, records 15-plus open-market S-coded sales spanning $361.50 to $368.56 across two trading days. The block reduced Ronda Stryker's directly-held position from 2,582,571 shares to 2,207,331 shares — a 14.5% trim of the directly-held portion, not an exit.

That distinction matters. Ronda Stryker is the granddaughter of company founder Homer Stryker; her directly-held Form 4 line is one of several reporting layers that map the family's beneficial ownership. The 13D/A she filed on April 14 — covering 4.0% beneficial ownership totaling 15,223,331 shares — captures a much wider economic interest, including positions held through trusts and other structures the Form 4 transactions ledger does not surface day-to-day.

The Greenleaf Trust block is the other half of the story

Just one week after the February S transactions cleared, Greenleaf Trust filed a 13G/A on February 11, 2026 reporting a 4.4% beneficial position totaling 16,801,654 shares. The trust is the Kalamazoo, Michigan-based fiduciary that has long served as the family's wealth platform; its $10.2 billion in 13F-reportable assets makes the SYK position roughly 60% of its disclosed equity book at current prices. That concentration is not coincidental — Greenleaf's existence is tied to managing the family's economic interest in Stryker.

Adding the two declared blocks together — Ronda Stryker's 4.0% and Greenleaf's 4.4% — gives the visible Stryker-family economic stake roughly 8.4% of the company, on the order of $11.7 billion at the May 9 close. The February tape, in that frame, looks less like a director "dumping shares" and more like a routine liquidity event sized inside a position that remains decisively long.

The Vanguard reshuffle that hit the same window

The April 30, 2026 Schedule 13G from Vanguard Capital Management LLC showed a 6.73% Stryker stake totaling 25,802,180 shares — the largest single institutional disclosure in the post-restructure window. That filing followed a March 27 13G/A from the older Vanguard Group umbrella reporting its position at zero, mirroring the same family-rebrand pattern that touched several other large-caps this spring (including Zoom and Boston Scientific). It is a reporting realignment, not net selling. Both Vanguard entities are passive index complexes, and their position size on SYK reflects the stock's weight in S&P 500 and total-market funds — not a discretionary view.

Why Q1 2026 earnings re-anchored the trim

Ronda Stryker's selling window straddled the company's Q1 print: revenue of $6.02 billion (+2.6% YoY), operating profit of $936 million (+11.8%), and diluted EPS of $1.93 (+14.2%). Organic sales growth of 11.0% — the metric medtech analysts use to strip out divestiture and currency noise — exceeded BTIG's modeled estimate by 2.6%. The board declared a $0.88 quarterly dividend, a 4.8% lift on the prior year. Against that operating backdrop, a directors's tax-and-diversification trim is the kind of liquidity event one would expect to see in a 10b5-1 trading window scheduled around the print.

Cross-checking the ownership claim

The numbers an investor can rely on in this story:

• 2,207,331: Ronda Stryker's directly-held SYK balance after the February S transactions, per Form 4 Table I.
• 15,223,331: Beneficial ownership reported in her April 14 Schedule 13D/A — the operative figure for control-block analysis.
• 16,801,654: Greenleaf Trust's reported holding per the February 11 13G/A.
• ~$11.7 billion: Combined Stryker-family + Greenleaf-Trust economic stake at $367.

The "Stryker director sells $137M" framing that ran on insider feeds reads only the Form 4 transactions ledger. It misses the 13D/A. It misses Greenleaf. It misses the post-Q1 dividend hike. The accurate read is that the family complex around SYK trimmed roughly 1.2% of its visible economic position into a strong operational tape — a posture far closer to "rebalancing into strength" than "fading the medtech cycle." Ronda Stryker's trading history shows zero open-market purchases against 1,431 lifetime transactions, which is the dataset's clearest reminder that absence of buying is not the same thing as absence of conviction.

What to watch from here

• Late July 2026: Stryker Q2 2026 earnings. Watch organic sales growth against the Q1 11.0% benchmark and operating margin against the Q1 15.5% rate (operating profit $936M ÷ revenue $6.02B).
• Q3 2026 13F filings: Whether the new Vanguard family disclosures consolidate or further fragment SYK exposure — the underlying ownership weight is unlikely to materially change, but the reporting structure will inform how investors track it on the stock holders page.
• Schedule 13D/A renewal: Any future amendment from Ronda Stryker moving away from the 4.0% threshold would be the first material change to the family's disclosed economic position. The April 14 filing reset the clock.

The full medtech-large-cap institutional setup, including Stryker's 13D/G coverage, is tracked on the institutional signal feed. For a primer on how Schedule 13D/A renewals differ from passive 13G filings — the distinction underpinning the Stryker-family read — see the explainer hub.